TAVI in 2016: the year the treatment of aortic stenosis was transformed

Chairpersons: G. GEROSA, S. WINDECKER


To learn from the latest evidence in the field of TAVI
To understand which patient populations would either benefit from surgical aortic valve replacement or TAVI
To learn how the TAVI procedure can be further streamlined with new generation delivery systems and valves


Session objectives

G. Gerosa

TAVI in 2016: what is the data that justifies transformational change?

M. Gilard

When should surgical aortic valve replacement still be considered in intermediate risk patients?

V. Falk

Recorded case from St. Thomas’ Hospital - London, United Kingdom

S. Windecker

LIVE demonstration from St. Thomas’ Hospital - London, United Kingdom

Optimising the in-hospital patient pathway

J. Reinöhl

Optimising TAVI through technological innovation

S. Windecker

Session evaluation and key learnings

S. Windecker


More from Edwards Lifesciences

Visit website